In a landmark development, the US Department of Health and Human Services (HHS) has recently recommended a significant change in the scheduling of cannabis, proposing to move it from a Schedule 1 drug to a Schedule 3 drug. This recommendation has sparked debates and discussions across the nation about the potential implications of such a shift. In this blog, we will delve into the intricacies of drug scheduling, the actors involved, the significance of this change, and the pros and cons associated with the de-scheduling of cannabis.
How are drugs currently scheduled through the Controlled Substance Act?
The scheduling of drugs in the United States is governed by the Controlled Substances Act (CSA) of 1970, which classifies substances into five schedules based on their perceived medical utility, potential for abuse, and safety. Schedule 1 is the most restrictive category, while Schedule 5 is the least restrictive. Currently, cannabis is classified as a Schedule 1 drug, indicating that it is considered to have a high potential for abuse, no accepted medical use, and a lack of accepted safety for use under medical supervision.
Schedule 1, where cannabis currently resides, is a classification that places it alongside substances like heroin and LSD. This classification has long been a point of contention in the United States, as it places cannabis in the same category as drugs that are widely recognized as highly addictive and dangerous with no accepted medical use.
Schedule 2 drugs, on the other hand, include substances like cocaine and opioids, which are acknowledged to have some medical applications but are subject to strict regulations due to their potential for abuse and addiction. The placement of cannabis in Schedule 1 has been a barrier to conducting extensive research into its medical potential, as it imposes stringent restrictions on obtaining research permits and funding for studies.
Schedule 3 drugs, such as certain anabolic steroids and medications like Vicodin, are recognized as having a moderate to low potential for abuse and accepted medical uses. The proposed move of Cannabis from Schedule 1 to Schedule 3 signifies a significant shift in how cannabis is perceived by federal authorities.
Schedule 4 drugs are substances that have a lower potential for abuse relative to Schedule 1, 2, and 3 drugs, but they still carry a risk of physical or psychological dependence. These substances have accepted medical uses and are commonly prescribed by healthcare professionals. Schedule 4 drugs include medications such as Xanax (alprazolam), Ativan (lorazepam), and Valium (diazepam), which are primarily used to treat anxiety and panic disorders. They are subject to regulations to minimize the potential for misuse or diversion.
Schedule 5 drugs are the least restrictive category under the CSA. These substances have a very low potential for abuse relative to the higher schedules and are primarily used for medicinal purposes. Schedule 5 drugs include medications like cough preparations containing less than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC, Phenergan with Codeine) and medications containing low doses of opiate medications for antidiarrheal purposes (Lomotil, Motofen).
Unlike Schedule 1 and 2 drugs, which are subject to strict regulations and oversight, Schedule 4 and 5 drugs are more readily available with a prescription from a licensed healthcare provider. The primary focus with these schedules is to ensure that these substances are used for legitimate medical purposes while minimizing the risk of abuse and dependence.
What are the steps to take this from a simple recommendation to legally making Cannabis a Schedule 3 drug?
Recommendations are a great first step but a far cry from actually rescheduling Cannabis. In order to do that, we have to understand the steps involved and who ultimately makes those decisions. The process of rescheduling a controlled substance like cannabis is a multi-step, thorough, and often lengthy process, with the Drug Enforcement Administration (DEA) holding the ultimate authority for making this decision.
- HHS Recommendation: The initial step in the rescheduling process begins with the recommendation from the US Department of Health and Human Services (HHS). This recommendation is pivotal, as it is based on comprehensive evaluations of scientific, medical, and public health data. The HHS analyzes research findings, reviews existing literature, and consults with experts to determine whether the current scheduling of a substance aligns with its potential for abuse, medical utility, and safety.
- DEA Evaluation: Once the HHS makes its recommendation, it is then forwarded to the Drug Enforcement Administration (DEA). The DEA is responsible for enforcing the Controlled Substances Act and has the authority to reschedule or reschedule controlled substances. Upon receiving the recommendation, the DEA conducts its own exhaustive review.
- Rigorous Assessment: The DEA’s review process involves a rigorous examination of the scientific and medical evidence surrounding the substance in question. This includes scrutinizing studies, clinical trials, anecdotal evidence, and any potential risks associated with the substance’s use. The agency also takes into account public comments and feedback during this process, allowing for a comprehensive evaluation from various stakeholders.
- Final Determination: After the DEA has completed its review, it makes the final determination regarding the scheduling of the substance. This decision can involve maintaining the current schedule, rescheduling to a different schedule, or de-scheduling the substance entirely. The DEA’s decision is based on its assessment of the evidence and whether the substance’s current classification aligns with scientific understanding and public health considerations.
How the decision is made
It’s important to note that the DEA’s decision-making process is intended to be impartial and based on scientific evidence rather than political or ideological factors. However, the process can be influenced by changing attitudes, new research findings, and evolving public perceptions.
In the case of cannabis, the HHS’s recommendation to move it from Schedule 1 to Schedule 3 reflects a significant shift in how the federal government views the plant. If the DEA were to concur with this recommendation, it would signal a change in federal policy that could have far-reaching implications for medical research, patient access, and the legal status of cannabis in the United States. As the evaluation process unfolds, it will be closely watched by individuals, researchers, and stakeholders who have a vested interest in the future of cannabis regulation. The fact is, we are only at the tip of the iceberg when it comes to the actual rescheduling of Cannabis.
Why does this change matter, what does it represent?
There are many ways rescheduling or completely de-scheduling Cannabis could change the lives of the American people. Here are just a few options to expand on when considering how opening up Cannabis and making it available to all, might be helpful.
Access to Medical Marijuana:
The reclassification of cannabis from Schedule 1 to Schedule 3 holds the promise of transforming the landscape of medical marijuana in the United States. Currently, the Schedule 1 classification severely limits scientific research into the potential medical benefits of cannabis. Researchers face numerous hurdles in obtaining research permits, funding, and access to a consistent supply of cannabis for studies. This hinders our understanding of the plant’s therapeutic potential and limits the development of new treatments.
By moving cannabis to a lower schedule, the federal government could signal its commitment to advancing medical research. This could lead to more comprehensive studies on cannabis and its various compounds, such as CBD and THC, potentially unlocking new treatments for a wide range of medical conditions. Patients suffering from chronic pain, epilepsy, multiple sclerosis, and other ailments could see improved access to evidence-based treatments that incorporate cannabis derivatives.
Reduced Criminal Penalties:
The criminalization of cannabis has led to countless arrests and convictions, disproportionately affecting communities of color. De-scheduling cannabis could result in a significant reduction in criminal penalties for possession and use. Individuals with non-violent cannabis-related offenses may no longer face the severe legal consequences that often result in lifelong barriers to employment, housing, and education.
Furthermore, the burden on the criminal justice system, including law enforcement, courts, and prisons, would be alleviated. This could free up resources to focus on more pressing matters and contribute to a more equitable and efficient justice system.
The cannabis industry has experienced remarkable growth in states where it has been legalized for either medical or recreational use. A shift from Schedule 1 to Schedule 3 would likely lead to reduced regulatory restrictions, potentially fueling further economic growth and job creation.
Legalizing and regulating the cannabis industry at the federal level could open up opportunities for legitimate businesses to thrive, resulting in increased tax revenue for local and state governments. It could also create a broader range of job opportunities, from cultivation and distribution to retail and research roles, benefiting local economies.
The proposed rescheduling of cannabis carries significant ramifications for multiple stakeholders. From patients seeking effective medical treatments to researchers aiming to uncover the full therapeutic potential of cannabis compounds, the potential for change is substantial. Simultaneously, a shift in scheduling could lead to reduced criminal penalties and offer economic benefits, particularly for the burgeoning cannabis industry. As the debate over cannabis policy continues to evolve, it remains a critical topic that will shape the future of healthcare, justice, and the economy in the United States.
What are the pros and cons of de-scheduling cannabis?
- Research Advancements: Rescheduling could facilitate further research into the potential medical benefits of cannabis, potentially leading to new treatments and therapies.
- Criminal Justice Reform: De-scheduling could lead to a reduction in arrests and convictions related to cannabis possession, reducing the strain on the criminal justice system.
- Economic Benefits: A less restrictive schedule could stimulate economic growth by allowing for expanded cultivation, distribution, and sales of cannabis products.
- Safety Concerns: Critics argue that de-scheduling may lead to increased access to cannabis, potentially raising concerns about misuse, impaired driving, and public health risks. Education will be key in both gaining the public’s trust over a plant that has long since been associated with other Schedule 1 drugs as well as ensuring safe usage and proper dosing in what is certainly an ever evolving landscape of modern cannabis consumption.
- Federal vs. State Conflicts: Cannabis is legal for medical or recreational use in many states, but federal prohibition persists. Rescheduling may not fully resolve the conflict between state and federal laws. Beyond that, What does taxation for the states look like after a rescheduling and potentially legalization of cannabis?
- Regulatory Challenges: The transition from Schedule 1 to a lower schedule could pose regulatory challenges, including product quality control, taxation, and marketing restrictions. Right now, we handle this well on a state-to-state level, but if the government federally legalizes cannabis after rescheduling, all the growing pains we went through to get seed-to-sale tracking systems in place might have to happen all over again.
To be clear, the HHS recommendation to reschedule cannabis from a Schedule 1 to a Schedule 3 drug really does mark a significant development in the ongoing debate over cannabis policy in the United States. And while it could offer numerous benefits such as expanded research opportunities and criminal justice reform, it also raises concerns about public safety and regulatory complexities. The final decision by the DEA will shape the future of cannabis in the United States, affecting the lives of millions of Americans and the trajectory of the cannabis industry. Stay tuned for updates as this important issue unfolds.
Here are a few sources about rescheduling Cannabis that you might find interesting:
- National Institute on Drug Abuse (NIDA) – Marijuana as Medicine: This government resource provides information on the current state of research and policies regarding the medical use of cannabis. It offers insights into the scientific aspects of cannabis and its potential therapeutic benefits.
- Website: NIDA – Marijuana as Medicine
- The Brookings Institution – “The medical marijuana mess: A prescription for fixing a broken policy”: This report delves into the complex issues surrounding the scheduling of cannabis and offers policy recommendations for a more rational approach to cannabis in the United States.
- Drug Enforcement Administration (DEA) – Controlled Substances Act: The DEA’s website provides information on the Controlled Substances Act, which governs the scheduling of drugs in the United States. It offers details on the legal framework and criteria used for drug scheduling decisions.
- Website: DEA – Controlled Substances Act
- NORML – National Organization for the Reform of Marijuana Laws: NORML is an advocacy group focused on cannabis policy reform. Their website offers a wealth of information on cannabis-related issues, including updates on legislative changes and advocacy efforts.
- Website: NORML
- PubMed – Cannabis Research: For those interested in scientific studies and research articles on cannabis, PubMed is a valuable resource. It provides access to a vast collection of peer-reviewed research papers related to the medical and therapeutic aspects of cannabis.
- Website: PubMed – Cannabis Research
Substance offers online ordering and curbside pickup for dabs and other fine products at all dispensary locations throughout Bend, OR, off I-5 in Cottage Grove, OR, and now at our newest location in Springfield, OR.